肿瘤坏死因子受体超家族成员9(TNFRSF9)重组蛋白说明书-分析方法-资讯-生物在线

肿瘤坏死因子受体超家族成员9(TNFRSF9)重组蛋白说明书

作者:上海沪震实业有限公司 2023-04-25T00:00 (访问量:918)

 肿瘤坏死因子受体超家族成员9(TNFRSF9)重组蛋白说明书

Recombinant Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9) 

[ DESCRIPTION ]

 Protein Names: Tumor Necrosis Factor Receptor Superfamily, Member 9

 Synonyms: TNFRSF9, CD137, ILA

Species: Human

Size: 100µg

Source:Escherichia coli-derived

Subcellular Location :Membrane; Single-pass type I membrane protein.

[ PROPERTIES ]

Residues: Asn40~Glu153 with N-terminal His-Tag.

Grade & Purity: >95%, 14 kDa as determined by SDS-PAGE reducing conditions.

 Formulation: Supplied as liquid form in Phosphate buffered saline(PBS), pH 7.4.

 Endotoxin Level: <1.0 EU per 1μg (determined by the LAL method).

Applications: SDS-PAGE; WB; ELISA; IP.

(May be suitable for use in other assays to be determined by the end user.)

Predicted Molecular Mass: 13.9 kDa

Predicted isoelectric point: 8.3

[ PREPARATION ]

Reconstitute in sterile PBS, pH7.2-pH7.4.

[ STORAGE AND STABILITY ]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8ºC for one month.

Aliquot and store at -80ºC for 12 months.

 

 

Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate wasdetermined by accelerated thermal degradation test, that is, incubate the protein at 37ºC for 48h, and no obviousdegradation and precipitation were observed. (Referring from China Biological Products Standard, which wascalculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date underappropriate storage condition.

[ SEQUENCES ]

The target protein is fused with N-terminal His-Tag, its sequence is listed below. 

MGHHHHHHSGSEF-N RNQICSPCPP NSFSSAGGQR TCDICRQCKG VFRTRKECSS TSNAECDCTP GFHCLGAGCSMCEQDCKQGQ ELTKKGCKDC CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKE

本产品仅供科研使用。不能用于人和动物治疗等其它临床诊断使用

上海沪震实业有限公司 商家主页

地 址: 上海市闵行区闵北路88弄1-30号第22幢AQ136室

联系人: 鲍丽雯

电 话: 021-60345367

传 真: 021-60345367

Email:www.shzbio.net

相关咨询
ADVERTISEMENT